Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
enGene Holdings ( (ENGN) ) just unveiled an update.
On September 30, 2025, enGene Holdings announced the appointment of Dr. Hussein Sweiti as Chief Medical Officer. Dr. Sweiti, a seasoned surgical oncologist, brings extensive experience in oncology clinical research and regulatory submissions, having recently led a successful FDA approval for a bladder cancer treatment at Johnson & Johnson. His appointment is expected to strengthen enGene’s clinical development and regulatory capabilities as the company prepares for a Biologics License Application submission for detalimogene in the second half of 2026. This strategic move underscores enGene’s commitment to advancing its investigational candidate for NMIBC and enhancing its potential for commercialization.
The most recent analyst rating on (ENGN) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on enGene Holdings stock, see the ENGN Stock Forecast page.
Spark’s Take on ENGN Stock
According to Spark, TipRanks’ AI Analyst, ENGN is a Neutral.
enGene Holdings shows significant financial challenges, with no revenue generation and persistent losses impacting both income and cash flow statements. Technical indicators suggest bearish momentum, with the stock underperforming key moving averages. The valuation is further hampered by a negative P/E ratio and absence of dividends. These factors collectively result in a low overall stock score, highlighting the company’s urgent need to establish a revenue model and improve operational efficiency.
To see Spark’s full report on ENGN stock, click here.
More about enGene Holdings
enGene Holdings Inc. is a clinical-stage biotechnology company focused on genetic medicine, aiming to deliver therapeutics to mucosal tissues and other organs to address diseases with high clinical needs. Its lead program is detalimogene voraplasmid for non-muscle invasive bladder cancer (NMIBC), developed using the proprietary Dually Derivatized Oligochitosan® (DDX) platform.
Average Trading Volume: 167,678
Technical Sentiment Signal: Buy
Current Market Cap: $330.2M
See more insights into ENGN stock on TipRanks’ Stock Analysis page.